CervoMed completes enrollment in Phase 2a trial of neflamapimod for nonfluent variant primary progressive aphasia
CervoMed announced on July 9, 2026 that it has completed enrollment in a Phase 2a study of neflamapimod for the treatment of nonfluent variant primary progressive…